Novo Nordisk (NYSE: NVO) details 7.8M B shares repurchased in 2026

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026.

As of 20 March 2026, Novo Nordisk has repurchased a total of 7,847,992 B shares at an average price of DKK 266.53 per share, for a total transaction value of DKK 2,091,696,255. Following these transactions, Novo Nordisk holds 25,237,791 B shares as treasury shares, equal to 0.6% of the 4,465,000,000 A and B shares outstanding, including treasury shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 03/23/2026 - 08:56 AM Learn about SEC filing dates

FAQ

What is the size and timing of Novo Nordisk (NVO) 2026 share repurchase programme?

Novo Nordisk expects to repurchase B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026. Within this, a sub-programme of up to DKK 3.8 billion runs from 4 February 2026 to 4 May 2026.

How many Novo Nordisk (NVO) shares have been repurchased as of 20 March 2026?

As of 20 March 2026, Novo Nordisk has repurchased 7,847,992 B shares since 4 February 2026. These shares were bought at an average price of DKK 266.53 per B share, for a total transaction value of DKK 2,091,696,255.

What proportion of Novo Nordisk (NVO) share capital is held as treasury shares?

After the reported transactions, Novo Nordisk owns 25,237,791 B shares as treasury shares. This holding corresponds to 0.6% of the company’s total share capital of 4,465,000,000 A and B shares, including treasury shares.

What recent daily buybacks has Novo Nordisk (NVO) completed in March 2026?

Between 16 and 20 March 2026, Novo Nordisk repurchased between 250,000 and 260,000 B shares per day. Daily average purchase prices ranged from DKK 235.26 to DKK 250.48, with individual daily transaction values around DKK 60–62 million.

Under which regulatory framework is Novo Nordisk (NVO) conducting its repurchase programme?

The share repurchase programme was initiated under Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052. These so‑called Safe Harbour Rules define conditions for buybacks to support orderly market trading.

Where can investors find detailed Novo Nordisk (NVO) buyback transaction data?

Detailed information for each transaction under the share repurchase programme is published on novonordisk.com. Investors can review individual trading dates, number of B shares repurchased, average purchase prices and related transaction values on the company’s website.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

March 23, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 16 March 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	6,577,992		1,783,540,174
16 March 2026	250,000	247.46	61,865,500
17 March 2026	250,000	250.48	62,621,066
18 March 2026	250,000	242.80	60,698,999
19 March 2026	260,000	237.70	61,802,202
20 March 2026	260,000	235.26	61,168,314
Accumulated under the programme	7,847,992		2,091,696,255

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 25,237,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 20 March 2026, Novo Nordisk has since 4 February 2026 repurchased a total 7,847,992 B shares at an average share price of DKK 266.53 per B share equal to a transaction value of DKK 2,091,696,255.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. 

Contacts for further information

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	lzsk@novonordisk.com
Investors:
Michael Novod	Jacob Martin Wiborg Rode
+45 3075 6050	+45 3075 5956
nvno@novonordisk.com	jrde@novonordisk.com
Max Ung	Sina Meyer
+45 3077 6414	+45 3079 6656
mxun@novonordisk.com	azey@novonordisk.com
Alex Bruce	Christoffer Sho Togo Tullin
+45 3444 2613	+45 3079 1471
axeu@novonordisk.com	cftu@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 20 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: March 23, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer